MBX Biosciences Dirección

Dirección controles de criterios 1/4

El CEO de MBX Biosciences es Steve Hoerter, nombrado en Jul 2026, tiene una permanencia de 1.25 años. posee directamente un 0.067% de las acciones de la empresa, con un valor de $1.86M. La antigüedad media del equipo directivo y de la junta directiva es de 0.9 años y 2.1 años, respectivamente.

Información clave

Steve Hoerter

Chief Executive Officer (CEO)

US$1.0m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	0.07%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	2.1yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • Jul 06

MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)

Summary I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical profile and differentiated dosing convenience. MBXX's Precision Endocrine Peptide platform enables longer-acting, less frequent dosing, addressing key safety and compliance issues in hypoparathyroidism and obesity. Canvuparatide's Phase 2 data show strong efficacy and patient benefit, but Phase 3 must address PK variability and long-term calcium control risks. MBXX's obesity pipeline offers asymmetric upside, while $440M cash extends runway into 2029, mitigating near-term financing risk. Canvuparatide's phase 3 readout comes with risk, similar to recent Eneboparatide failing phase 3 trial (although their ph2 was positive), so we see MBX as a speculative buy. Read the full article on Seeking Alpha

Artículo de análisis • Jun 17

MBX Biosciences (MBX) Stock Looks Fully Valued After New Phase 2 Data

MBX Biosciences (MBX) has drawn fresh attention after publishing full Phase 2 Avail and one-year open-label data for its lead candidate canvuparatide in chronic hypoparathyroidism, alongside confirming plans for a pivotal Phase 3 trial. See our latest analysis for MBX Biosciences. Against this backdrop, MBX Biosciences stock has seen strong momentum, with a 7 day share price return of 29.36% and a 90 day share price return of 41.01%, while the 1 year total shareholder return is very large at...

Artículo de análisis • Jun 28

Companies Like MBX Biosciences (NASDAQ:MBX) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Artículo de análisis • Mar 13

We're Not Very Worried About MBX Biosciences' (NASDAQ:MBX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Seeking Alpha • Nov 14

MBX Biosciences: Decent Potential For Lead Indication, But Need More Data

Summary MBX Biosciences, a recent IPO, develops precision peptide therapies for endocrine and metabolic disorders, with lead asset MBX 2109 in phase 2 for Hypoparathyroidism. MBX 2109, a once-weekly PTH replacement therapy, shows promising phase 1 results with stable drug concentration and potential to improve patient compliance over daily treatments. Financially, MBX has a market cap of $784mn and a cash runway of 12-14 quarters, sufficient to reach phase 2 trial data by Q3 2025. Despite promising prospects, I will wait for phase 2 trial data and pricing information before considering a position, while monitoring Yorvipath's market performance. Read the full article on Seeking Alpha

CEO

Steve Hoerter (55 yo)

no data

Permanencia

US$999,986

Compensación

Mr. Steven L. Hoerter, also known as Steve, is President and Chief Executive Officer of MBX Biosciences, Inc. from July 13, 2026. He was Independent Director of MBX Biosciences, Inc. from April 2025 until...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Steven Hoerter	Executive Chairperson	no data	US$999.99k	0.067% $ 1.9m
Peter Hawryluk	Executive Officer	no data	US$2.99m	2.55% $ 70.8m
Salomon Azoulay	Chief Medical Officer	2.1yrs	US$1.47m	0.031% $ 861.1k
John Smither	Chief Financial Officer	less than a year	sin datos	sin datos
Pete De Spain	Senior Vice President of Investor Relations & Corporate Communications	less than a year	sin datos	sin datos
Michelle Graham	Chief Human Resources Officer	2.8yrs	sin datos	sin datos
Michael Dorato	Sr. Vice President of Discovery & Non-Clinical Development	1.9yrs	sin datos	sin datos
Chatan Charan	Senior VP of Pharmaceutical Development & Chemistry	1.3yrs	sin datos	sin datos
Mark Hope	Senior Vice President of Regulatory & Quality	1.3yrs	sin datos	sin datos
Andreas Moraitis	Senior Vice President of Clinical Development	1.1yrs	sin datos	sin datos
Karen Basbaum	Chief Business Officer	less than a year	sin datos	sin datos
Mark Soued	Chief Commercial Officer	less than a year	sin datos	sin datos

0.9yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MBX no se considera experimentado ( 0.9 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Steven Hoerter	Executive Chairperson	1.3yrs	US$999.99k	0.067% $ 1.9m
Patrick Heron	Independent Director	6yrs	US$220.95k	0% $ 0
Edward Mathers	Independent Director	6yrs	US$196.19k	0% $ 0
Willard Dere	Member of Scientific Advisory Board	2.1yrs	sin datos	sin datos
Ora Pescovitz	Independent Director	4.3yrs	US$198.95k	0.051% $ 1.4m
Michael Econs	Member of Scientific Advisory Board	2.1yrs	sin datos	sin datos
Tiba Aynechi	Independent Director	3.7yrs	US$200.69k	0% $ 0
Steven Ryder	Independent Director	2.4yrs	US$194.95k	0% $ 0
Laurie Stelzer	Independent Director	less than a year	sin datos	sin datos
John Bilezikian	Member of Scientific Advisory Board	no data	sin datos	sin datos
Mishaela Rubin	Member of Scientific Advisory Board	2.1yrs	sin datos	sin datos
Dolores Shoback	Member of Scientific Advisory Board	2.1yrs	sin datos	sin datos

2.1yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de MBX no se considera experimentada (2.1 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/07/23 00:36
Precio de las acciones al final del día	2026/07/23 00:00
Beneficios	2026/03/31
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

MBX Biosciences, Inc. está cubierta por 14 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Eliana Merle	Barclays
Jonathan Wolleben	Citizens JMP Securities, LLC
Corinne Johnson	Goldman Sachs

MBX Biosciences Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

MBX Biosciences, Inc. Announces the Appointment of John Smither as Chief Financial Officer, Effective July 13, 2026

Chief Medical Officer notifies of intention to sell stock

MBX Biosciences, Inc., Annual General Meeting, Jun 04, 2026

MBX Biosciences, Inc. Appoints Karen Basbaum As Chief Business Officer

MBX Biosciences, Inc. Announces Board and Committee Changes

Mbx Biosciences, Inc. Announces Changes to Its Board, Effective from October 31, 2025

Recent updates

Price target increased by 7.1% to US$74.00

MBX Biosciences, Inc. Announces the Appointment of John Smither as Chief Financial Officer, Effective July 13, 2026

MBX Biosciences Names Steve Hoerter CEO and John Smither CFO in Leadership Transition

Imapextide Wins FDA Orphan Drug Status as MBX Biosciences Advances in Rare Disease Trials

MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)

MBX Biosciences, Inc.(NasdaqGS:MBX) dropped from Russell Microcap Value Benchmark Index

MBX Biosciences (MBX) Stock Looks Fully Valued After New Phase 2 Data

MBX Biosciences Shares Fall Despite Encouraging One-Year Canvuparatide Study Results

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit Of Once-Weekly Canvuparatide As A Potential PTH Replacement Therapy In Chronic Hypoparathyroidism

Price target increased by 10% to US$69.09

Chief Medical Officer notifies of intention to sell stock

MBX Biosciences Prepares for Phase 3 Canvuparatide Trial With Strong Cash Position

MBX Biosciences, Inc., Annual General Meeting, Jun 04, 2026

Price target increased by 7.8% to US$65.89

New major risk - Revenue and earnings growth

MBX Biosciences, Inc. Appoints Karen Basbaum As Chief Business Officer

MBX Biosciences, Inc. Announces Board and Committee Changes

Price target increased by 9.2% to US$64.43

Mbx Biosciences, Inc. Announces Changes to Its Board, Effective from October 31, 2025

MBX Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

CEO, President & Director exercised options to buy US$3.6m worth of stock.

Insider recently bought US$265k worth of stock

New major risk - Shareholder dilution

MBX Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $199.94499 million.

MBX Biosciences, Inc. Plans to Initiate A Phase 3 Clinical Trial of Once-Weekly Canvuparatide in 2026

New major risk - Share price stability

Price target increased by 32% to US$49.43

MBX Biosciences, Inc. Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responsonder Rate at 12 Weeks;79% Responder Rate at 6 Months in Open-Label Extension

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

New major risk - Revenue and earnings growth

MBX Biosciences, Inc.(NasdaqGS:MBX) dropped from Russell Small Cap Comp Growth Index

Companies Like MBX Biosciences (NASDAQ:MBX) Are In A Position To Invest In Growth

MBX Biosciences, Inc Appoints Andreas Moraitis as Senior Vice President of Clinical Development

MBX Biosciences, Inc. Announces IND Submission of MBX 4291, its Long-Acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

MBX Biosciences, Inc. to Present At the American Diabetes Association 85Th Scientific Sessions

MBX Biosciences, Inc. Announces Departure of Carl L. Gordon from the Company's Board of Directors, Effective June 5, 2025

MBX Biosciences, Inc., Annual General Meeting, Jun 05, 2025

MBX Biosciences, Inc. Announces the Appointment of Steve Hoerter as an Independent Director, Effective April 7, 2025

We're Not Very Worried About MBX Biosciences' (NASDAQ:MBX) Cash Burn Rate

MBX Biosciences, Inc. Announces Management Appointments

MBX Biosciences, Inc. Completes Enrollment in Phase 2 Avail™? Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

CEO, President & Director recently bought US$535k worth of stock

MBX Biosciences, Inc. Announces Positive Phase 1 Topline Data for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia (PBH)

High number of new directors

MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism

Mbx Biosciences, Inc. Announces Last Subject Last Visit in Phase 1 Trial of Mbx 1416 for the Treatment of Post-Bariatric Hypoglycemia